TO EVALUATE THE SAFETY, TOLERABILITY, PULMONARY DEPOSITION, PHARMACOKINETICS AND PHARMACODYNAMICS OF CIPROFLOXACIN INHALE IN JAPANESE PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD, GOLD II-III):